|
Juliane Jurgensmeier Phone: +44 (0)1625 230789  Contact |
Dr. Juliane M Jürgensmeier graduated from the Albert-Ludwigs-University of Freiburg, Germany and afterwards obtained her PhD and initial postdoctoral training at the Institute for Virology in Freiburg working on TGF-beta signalling in cancer. She expanded her research expertise as a DFG-fellow at the Burnham Institute, La Jolla, California with Dr. John C. Reed, focussing on mitochondrial apoptosis signalling. In 1998, she was appointed Associate Professor at the Christian-Albrechts-University of Kiel, Germany, followed by Assistant Professor at the University of Köln, Germany. Her group focussed on the mechanisms of Bax-induced cytochrome c release from mitochondria in apoptosis and resistance to treatment-induced apoptosis in Morbus Hodgkin. In 2003, she moved to AstraZeneca in the UK and has since worked as a translational scientist on the development of anti-angiogenic agents for the treatment of cancer. She is presently a Principal Scientist and the global scientific and translational leader for a VEGF signalling inhibitor in late stage clinical development.
http://www.ncbi.nlm.nih.gov/pubmed?term=%22J%C3%BCrgensmeier%20JM%22%5BAuthor%5D AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world's most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
www.astrazeneca.com/about-us/The group at AstraZeneca will provide technical expertise in angiogenesis assays and methodology. Furthermore, tumor biomarkers, in particular vascular markers, have been a focus of research with various methods (including immunohistochemistry and ELISAs) have been developed to explore vascular markers in preclinical models as well as clinical samples. The Scientist-in-charge is a Translational Scientist at AstraZeneca and the Discovery and Translational Science leader on a global team responsible for the development of an anti-angiogenic agent for the treatment of cancer. She is responsible for preclinical data supporting the project as well as the biomarker strategy and its implementation in clinical development. The expertise at AstraZeneca will provide insight into translational science from preclinical to clinical stages of drug development.
Consortium
About TranSVIR
